Caplin Point Laboratories Limited

CAPLIPOINT

INE475E01026

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 12:26:01 08/07/2024 pm IST			5-day change	1st Jan Change
1,420 ^INR	-2.71%		-2.22%	+4.70%

11/06	Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer	CI
24/05	Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution	MT

Caplin Point Laboratories Limited Announces M Jayapal, Completed Tenure of Office as Whole-Time Director on March 28, 2018

March 29, 2018 at 05:37 pm IST

Caplin Point Laboratories Limited announced that Mr. M Jayapal, Whole-time Director of the company attained superannuation on the close of business hours on March 28, 2018. Therefore, Mr. M Jayapal has completed his tenure of office of Whole-time Director of the company.

Latest news about Caplin Point Laboratories Limited

Caplin Point Laboratories Limited Appoints Thiagaraja Manikandan as Chief Transformation & Digital Officer	11/06	CI
Caplin Point Arm Gets US FDA's Nod for Phenylephrine Hydrochloride Ophthalmic Solution	24/05	MT
Caplin Point Laboratories to Seek Acquisitions	16/05	CI
Transcript : Caplin Point Laboratories Limited, Q4 2024 Earnings Call, May 16, 2024	16/05
Caplin Point Laboratories Limited Declares an Interim Dividend for the Financial Year Ended March 31, 2024	16/05	CI
Caplin Point Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	16/05	CI
Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India	06/05	MT
Caplin Point Laboratories Limited Receives Colombia's INVIMA Approval for Its Softgel Capsules Division At Puducherry	06/05	CI
Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution	16/04	MT
Caplin Point Unit Receives US FDA Nod for Eye Treatment Medication	28/03	MT
Caplin Steriles Limited, A Subsidiary of Caplin Point Laboratories Limited Gets USFDA Approval for Ketorolac Tromethamine Ophthalmic Solution	28/03	CI
Caplin Point Laboratories Arm Starts Operations of Oncology Facility at Kakkalur, India	27/03	MT
Caplin One Labs Limited, a Wholly Owned Subsidiary of Caplin Point Laboratories Limited Successfully Completes New Oncology (Anti-Cancer) Facility, Commences Operations	27/03	CI
Transcript : Caplin Point Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024	09/02
Caplin Point Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Caplin Point Laboratories to Invest INR7 Billion in Tamil Nadu, India	08/01	MT
Caplin Point Unit Gets US FDA Final Approval for Generic Ear Infection Drug	08/01	MT
Caplin Point Laboratories Limited Announces Resignation of Hero Velladurai as President, R&D	14/12	CI
Transcript : Caplin Point Laboratories Limited, H1 2024 Earnings Call, Nov 09, 2023	09/11
Caplin Point Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Caplin Point Laboratories Limited Approves Final Dividend for the Year Ended March 31, 2023	22/23/22	CI
Caplin Point Unit's Injectable and Ophthalmic Plant in India Gets VAI Classification from US FDA	04/23/04	MT
Transcript : Caplin Point Laboratories Limited, Q1 2024 Earnings Call, Aug 08, 2023	08/23/08
Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	07/23/07	CI
Caplin Point Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023	07/23/07	CI

Chart Caplin Point Laboratories Limited

Duration

Period

More charts

Company Profile

Caplin Point Laboratories Limited is an India-based pharmaceutical company. The Company is engaged in producing, developing, and marketing a range of generic formulations and branded products and exporting to overseas markets. Its products include tablets, dry syrups (bottles), soft gels, capsules, suppositories, liquid syrups (bottles), liquid injectables in ampoules and vials, lyophilized vials, prefilled syringes (PFS), emulsion injection in ampoules and vials, ophthalmic droppers, pre-mix bags, topicals and sachets (liquids and powders). It also manufactures a range of ointments, creams, gels and lotions. Its principal research and development facilities are in Tamil Nadu, India. Its principal manufacturing facility is in Puducherry, India. It has presence in Latin America (LATAM), Southern Africa and Francophone Africa along with a presence in United States of America and European region. The Companyâs subsidiaries include Caplin Point Far East Limited and Caplin Steriles Limited.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Caplin Point Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,459 INR

Average target price

1,569 INR

Spread / Average Target

+7.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
CAPLIN POINT LABORATORIES LIMITED	+4.70%	1.33B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+24.13%	45.07B
OTSUKA HOLDINGS CO., LTD.	+30.84%	23.39B
SANDOZ GROUP AG	+24.13%	16.08B
CIPLA LIMITED	+19.76%	14.6B
ZYDUS LIFESCIENCES LIMITED	+69.58%	14.01B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.53%	5.64B
GEDEON RICHTER	+10.74%	4.89B

Generic Pharmaceuticals